Obamacare is racking up expenses, in particular, with the creation of insurance exchanges. In this video, David Williamson looks at this feature of Obamacare, and a possible free market solution. The problem is that these exchanges are proving more expensive than originally thought, up to an estimated $5.7 billion for 2014. No wonder less than half of the states in the country have come on board. One solution is an online insurance exchange. A form of such an exchange already exists. Will it work for a nationwide insurance market?�Hard to say. On the one hand, it could offer small businesses unprecedented access to insurance plans. On the other hand, an online market may simply offer those plans with the best commissions and not the best deals.� (NASDAQ: EHTH )
What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: What's Really Eating At America's Competitiveness. You��l also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
Hot Penny Stocks For 2015: Sunesis Pharmaceuticals Inc.(SNSS)
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company?s principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including Phase II clinical trial, known as VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II clinical trial, known as REVEAL-1 in previously untreated patients of age 60 years or older, as well as completed a Phase II single-agent trial of Vosaroxin in patients with platinum-resistant ovarian cancer. In addition, the company is conducting a Phase II/III trial, known as the Less Intensive 1 in patients older than 60 years with AML or high-risk myelodysplastic syndrome. It has a license agreement with Dainippon Sumitomo Pharma Co. , Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.
Advisors' Opinion:- [By Selena Maranjian]
The biggest new holdings are Virgin Media�and Constellation Brands. Other new holdings of interest include Sunesis Pharmaceuticals (NASDAQ: SNSS ) , which has many investors hopeful about the phase 3 trials of its leukemia drug vosaroxin, which could be a blockbuster.
- [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Sunesis Pharmaceuticals (NASDAQ: SNSS ) has received an alarming one-star ranking.
Hot Stocks To Invest In Right Now: Model N Inc (MODN)
Model N, Inc., incorporated on December 14, 1999, is a provider of revenue management solutions for the life science and technology industries. The Company�� solutions enable its customers to maximize revenues and reduce revenue compliance risk by transforming their revenue lifecycle from a series of tactical, disjointed operations into a strategic end-to-end process. The Company�� customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. Its solutions include two complementary suites of software applications, Revenue Management Enterprise and Revenue Management Intelligence. On January 18, 2012, the Company acquired certain assets of LeapFrogRx, Inc. (LeapFrogRx), a privately held cloud-based analytics solution provider for the pharmaceutical industry.
The Company provides solutions that span the organizational and operational boundaries of functions such as sales, marketing and finance, and serve as a system of record for key revenue management processes including pricing, contracts, rebates and regulatory compliance. Its application suites are purpose-built for the life science and technology industries and are designed to work with enterprise resource planning (ERP) and customer relationship management (CRM) applications that do not typically provide revenue management capabilities by enabling real-time pricing, managing contracts and automating channel incentives management, including rebates.
Revenue Management Enterprise suite
A broad set of transactional applications that serve as a system of record for, and automate the execution of revenue management processes such as incentive and rebate management, pricing and contracting. This suite includes its Price Management, Deal Management, Contract Management, Incentive and Rebate Management and Regulatory Compliance Management applications, which can be purchased together as a suite or as separate stand-alone applications.
Revenue Management Intelligence suiteA broad set of intelligence applications that provide the analytical insights to define and optimize revenue management strategies. This suite includes its Price Strategy, Brand Strategy, Channel Strategy, Managed Markets Strategy and International Reference Pricing applications, which can be purchased together as a suite or as separate stand-alone applications.
Advisors' Opinion:- [By Lee Jackson]
Model N Inc. (NYSE: MODN) develops applications, such as managed care and government pricing, for life science companies and channel incentives based on design wins for technology companies. The company’s customers use its application suites to manage mission-critical functions, such as pricing, contracting, incentives and rebates. The company had a recent initial public offering (IPO) that traded as high as $24.80 before badly missing earnings and being taken to the woodshed. Deutsche Bank still rates it as a stock to buy and has a $12 price target. The consensus target is at $15. The stock closed Friday at $9.88.
Hot Stocks To Invest In Right Now: Fresh Healthy Vending International Inc (VEND)
Fresh Healthy Vending International, Inc., formerly Green 4 Media, Inc., incorporated on June 8, 2011, is an eco-marketing and advertising company. The Company focuses on designing marketing and advertising campaigns utilizing natural media. The Company offers a range of natural advertising options, including Floor, Vertical, and Field media. The Company can contour grass, crops, sand, moss, or sea shells to produce designs and marketing messages.
Floor and field media involves the use of sand, chalk, snow, and specialized cleaning to create 100% environmentally sustainable messages and advertisements. Vertical media uses walls, buildings, or bridges to act as the canvas for its ad creations.
Advisors' Opinion:- [By James E. Brumley]
Given its 144% gain since the end of last year, with 7% of that move coming today, it wouldn't be tough to get excited about Fresh Healthy Vending International Inc. (OTCBB:VEND) ... excited enough to jump into a VEND position. Unfortunately, there are a bunch of tell-tale signs that today is a major (albeit short-term) top today, and we're very likely headed for a sizable correction beginning tomorrow.
Hot Stocks To Invest In Right Now: Receptos Inc (RCPT)
Receptos, Inc. (Receptos), incorporated on June 9, 2008, is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing therapeutics for immune disorders. The Company�� product candidates span three specialty disease areas. The Company�� lead asset, RPC1063, is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). Its second asset, RPC4046, is being developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. RPC1063 is an oral, once daily, selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator. RPC4046 is a monoclonal antibody selective to interleukin-13 (IL-13) and produced by recombinant deoxyribonucleic acid (DNA) technology.
As of December 31, 2012, RPC1063 was being tested in the Phase II portion of an accelerated design, randomized Phase II/III study for the treatment of RMS. In addition, Receptos has obtained special protocol assessment (SPA) agreement from the United States food and drug administration (FDA) on its clinical trial design for the planned Phase III portion of the Phase II/III study, as well as a second planned RMS Phase III study. RPC1063 is also being tested in a randomized Phase II study for the treatment of ulcerative colitis (UC), a gastrointestinal (GI) disea se.
As of December 31, 2012, the Company was enrolling a randomized Phase II study evaluating the ability of RPC1063 to induce clinical remission in patients with moderately-to-severely active UC called TOUCHSTONE. The Company�� second asset, RPC4046 for the treatment of EoE, builds upon its competencies in immunology and GI diseases. In-licensed from AbbVie Bahamas Ltd. and AbbVie Inc. (AbbVie) RPC4046 is a monoclonal antibody directed against the IL-13 target, which has been validated in Asthma, a predominantly allergic/immune-mediated disorder.
Advisors' Opinion:- [By John Udovich]
Small cap �biopharmaceutical stock Receptos Inc (NASDAQ: RCPT) was one of the many hot biotech IPOs of last year and its also up 72.4% since the start of this year alone, meaning its time to take a closer look at this small cap stock with potential treatments for Relapsing Multiple Sclerosis (RMS) and Inflammatory Bowel Disease (IBD) along with the performance of biotech ETF benchmarks like the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
Hot Stocks To Invest In Right Now: Emergent Biosolutions Inc. (EBS)
Emergent BioSolutions, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and commercialization of specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. It markets BioThrax, an FDA licensed vaccine for the prevention of anthrax disease; and RSDL (decontamination lotion) product for removal or neutralization of chemical warfare agents from the skin. The company�s development pipeline includes Anthrivig (Human Anthrax Immunoglobulin), a polyclonal anthrax therapeutic candidate; PreviThrax, a recombinant anthrax vaccine candidate, NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant); BioThrax with a novel adjuvant; and Thravixa (Fully Human Anthrax Monoclonal Antibody), a therapeutic being studied for use against symptomatic anthrax infection. In addition, it develops TRU-016, a humanized anti-CD37 therapeutic candidate, ba sed on its ADAPTIR (Modular Protein Technology) platform that is in Phase I/II clinical trials to treat chronic lymphocytic leukemia. Further, the company develops preclinical product candidates targeted for solid tumors, inflammatory bowel disease, graft versus host disease, rheumatoid arthritis, and a human vaccine to protect against influenza caused by a range of circulating H5 influenza strains. Emergent BioSolutions, Inc. was founded in 1998 and is headquartered in Rockville, Maryland.
Advisors' Opinion:- [By Stephen Quickel]
Emergent BioSolutions (EBS) is a far smaller specialist in bio-medical products for the military and commercial markets, including anthrax vaccine and decontamination agents. With revenues nearing $400 million, EBS is acquiring Canada's Cangene Corp. to expand its product line.
- [By Traders Reserve]
I discovered Emergent Bio Solutions (EBS) when I ran my proprietary P/E Gap model at the end of December. Without getting into the details, P/E Gap identifies stocks that have the potential to rally based on being significantly undervalued.
Hot Stocks To Invest In Right Now: Six Flags Entertainment Corporation New(SIX)
Six Flags Entertainment Corporation owns and operates regional theme, water, and zoological parks. The company?s parks offers various selection of state-of-the-art and traditional thrill rides, water attractions, themed areas, concerts and shows, restaurants, game venues, and retail outlets. It owns and operates 19 parks, including 17 parks in the United States; 1 park in Mexico City, Mexico; and 1 park in Montreal, Canada. The company was formerly known as Six Flags, Inc. and changed its name to Six Flags Entertainment Corporation in April 2010. Six Flags Entertainment Corporation was founded in 1971 and is based in Grand Prairie, Texas.
Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Vetal/Shutterstock Single-day admissions to some of the country's most popular theme parks hit $99 this summer. Tack on transportation, lodging and in-park purchases, and costs quickly add up. By the time the coasters have been conquered and your thrills have been chronicled on Facebook's (FB) Instagram, you're going to be out a lot of money. Let's dive into how to save some at the park this season. 1. Find the Local Discounter Amusement park chains and most theme park operators realize that you can't succeed without having a steady flow of locals. They often team up with area supermarkets or restaurants to offer discounted tickets. If you're heading to a local park, you probably know the area businesses offering discount admissions as either coupons you present at the gate or prepaid entrances. If you're heading out to a park while you're traveling, find the name of the grocery store or burger haven offering deals through the park's website, social media page or park forum. 2. Do the Math on a Season Pass For essentially the price of a one-day ticket, SeaWorld's (SEAS) "Fun Card" tickets are good for unlimited admissions through the end of the year at many of its parks. There are some blackout dates, and some annual pass holder perks like complimentary parking aren't included, but it's too cheap to ignore. Six Flags (SIX) and Cedar Fair (FUN) have annual passes that typically pay for themselves after the second or third visit. It will take longer to offset the purchase of Disney (DIS) or Comcast's (CMCSA) Universal annual passes. 3. Head Out With a Pass Holder If you and your family decide that a becoming an annual pass holder isn't the right call -- or it isn't in your budget -- see if you know anyone who's an annual pass holder and join them at the park. Attractions are always more fun with more people, and your pocketbook will probably thank you for this tip. Annual passes typically include free parking, and many premium varieties come discounts o
- [By Rick Munarriz]
Six Flags (NYSE: SIX ) hit an all-time high yesterday, a day after posting better-than-expected quarterly results in a blowout performance. Revenue climbed 32% to $87.5 million, fueled by a 41% spike in attendance. The regional amusement park operator's net loss narrowed to $1.23 a share. Analysts were buckled in, braced for a deficit of $1.46 a share on $68.2 million in revenue.
- [By Marc Bastow]
Entertainment theme park operator Six Flags (SIX) raised its quarterly dividend 4.4% to 47 cents per share, payable on Dec. 9 to shareholders of record as of Nov. 25.
SIX Dividend Yield: 5.14%
- [By John Kell]
Six Flags Entertainment Corp.(SIX) said its fourth-quarter revenue rose more than expected on higher admissions and an increase in in-park spending, sponsorships and accommodations. Shares edged up 3.3% to $39.50 premarket.
No comments:
Post a Comment